However, the activation of i NKT cells with their prototypical lipid ligand, -galactosylceramide (GalCer), has been observed to result in their amplification, which in turn has been demonstrated to induce effective weight loss [161, 162]
It acts as a coenzyme in various metabolic pathways and is involved in DNA synthesis and red blood cell production
Zepbound, a brand name of tirzepatide, is FDA-approved for weight management when combined with increased physical activity and a reduced-calorie diet in adults with: Obesity (BMI 30 or higher) Overweight (BMI 27 or higher with at least one weight-related condition such as high cholesterol levels, hypertension (high blood pressure), type 2 diabetes, and cardiovascular disease Moderate to severe obstructive sleep apnea (OSA) Mounjaro contains tirzepatide as an active ingredient and is approved by the U.S

Recent Trends in GLP-1 Use and Spending in Medicare Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, new data from the Centers for Medicare & Medicaid Services (CMS) shows that use and spending for these drugs under Medicare has grown substantially in recent years, reflecting their demonstrated effectiveness at treating type 2 diabetes and other conditions